Literature DB >> 20692643

Topography-guided conductive keratoplasty: treatment for advanced keratoconus.

Naoko Kato1, Ikuko Toda, Tetsuya Kawakita, Chikako Sakai, Kazuo Tsubota.   

Abstract

PURPOSE: To evaluate the use of topography-guided conductive keratoplasty in eyes with keratoconus.
DESIGN: Interventional case series.
METHODS: We examined 21 eyes in 21 patients with advanced keratoconus. Topography-guided conductive keratoplasty was performed with intraoperative monitoring of corneal astigmatism using a surgical keratometer. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), corneal topography, manifest refraction, intraocular pressure (IOP), corneal endothelial cell counts, complications, and eventual outcomes were evaluated.
RESULTS: UCVA (logarithm of the minimal angle of resolution [logMAR]), which was 1.65 ± 0.49 preoperatively, improved to 1.04 ± 0.64 at 1 week (P < .001) and 1.12 ± 0.61 at 1 month after surgery (P < .001). BSCVA, which was 1.02 ± 0.56 preoperatively, improved to 0.76 ± 0.65 at 1 week (P = .026) and 0.76 ± 0.60 at 1 month after surgery (P = .003). Manifest refraction, which was -15.13 ± 6.66 diopters (D) before surgery, declined to -9.97 ± 6.71 D at 1 month after surgery (P = .002). Although corneal topography reverted to the preoperative pattern and UCVA and BSCVA also regressed toward preoperative values, 12 of 21 eyes were better able to tolerate and conduct normal daily activities using contact lenses. Five subjects have undergone or are considering corneal transplantation after unsatisfactory postoperative results. No serious perioperative complication was observed.
CONCLUSIONS: Topography-guided conductive keratoplasty may be effective in reshaping corneal configuration in eyes with keratoconus, without serious complications, and possibly contributed to avoiding or delaying corneal transplantation.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20692643     DOI: 10.1016/j.ajo.2010.05.014

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

Review 1.  New clinical pathways for keratoconus.

Authors:  D M Gore; A J Shortt; B D Allan
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

2.  Outcomes of Conductive Keratoplasty Combined with Corneal Crosslinking in Advanced Ectatic Corneal Disease.

Authors:  Mazen M Sinjab; Roy S Rubinfeld; Kirsten Wagner; Edward C Parsons Jnr; Arthur B Cummings; Michael W Belin
Journal:  Clin Ophthalmol       Date:  2021-03-29

Review 3.  Updates on Managements for Keratoconus.

Authors:  Mehrdad Mohammadpour; Zahra Heidari; Hassan Hashemi
Journal:  J Curr Ophthalmol       Date:  2017-12-06

Review 4.  Combined Protocols for Corneal Collagen Cross-Linking with Photorefractive Surgery for Refractive Management of Keratoconus: Update on Techniques and Review of Literature.

Authors:  Angela Y Zhu; Albert S Jun; Uri S Soiberman
Journal:  Ophthalmol Ther       Date:  2019-10-11

Review 5.  Corneal cross-linking (CXL) combined with refractive surgery for the comprehensive management of keratoconus: CXL plus.

Authors:  Vardhaman P Kankariya; Ankita B Dube; Michael A Grentzelos; George A Kontadakis; Vasilios F Diakonis; Myrsini Petrelli; George D Kymionis
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

6.  Laboratory evaluation of selective in situ refractive cornea collagen shrinkage with continuous wave infrared laser combined with transepithelial collagen cross-linking: a novel refractive procedure.

Authors:  Anastasios John Kanellopoulos
Journal:  Clin Ophthalmol       Date:  2012-05-01

Review 7.  Keratoconus: current perspectives.

Authors:  Jayesh Vazirani; Sayan Basu
Journal:  Clin Ophthalmol       Date:  2013-10-14

8.  Comparison of penetrating keratoplasty outcomes with or without microwave thermokeratoplasty.

Authors:  Osamu Hieda; Koichi Wakimasu; Shigeru Kinoshita; Chie Sotozono
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.